47676 Federal Register / Vol. 62, No. 175 / Wednesday, September 10, 1997 / Notices

from 8:00 a.m. to approximately 1:00

p.m. for the review, discussion, and

evaluation of individual grant

applications. These applications and the

discussions could reveal confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning

individuals associated with the

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Ms. Mary Plummer, Executive

Secretary, NACHHD Council, 6100

Executive Boulevard, Room 5E03,

National Institutes of Health, Bethesda,

Maryland 20892–7510, Area Code 301,

594–7232, will provide a summary of

the meeting and a roster of Council

members as well as substantive program

information. Individuals who plan to

attend the open session and need

special assistance, such as sign language

interpretation or other reasonable

accommodations, should contact Ms.

Plummer.

(Catalog of Federal Domestic Assistance

Program Nos. [93.864, Population Research,

and 93.865, Research for Mothers and

Children], National Institutes of Health)

Dated: September 4, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–23893 Filed 9–9–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Deafness and

Other Communication Disorders;

Amended Notice of Meeting of the

National Deafness and Other

Communication Disorders Advisory

Council

Notice is hereby given of a change in

the September 11 meeting of the

National Deafness and Other

Communication Disorders Advisory

Council which was published on

August 7, 1997, 62 FR 42587.

The meeting was to have been a

closed meeting convened at 1 pm and

adjourned at 2 pm on September 11.

The meeting has been changed to a

partially closed meeting. The Council

will meet in open session from 1 pm to

approximately 1:45 pm to discuss a

meeting of the Work Group on Peer

Review. At approximately 1:45 pm the

meeting will be closed until

adjournment for the review of grant

applications.

(Catalog of Federal Domestic Assistance

Program No. 93.173 Biological Research

Related to Deafness and Communication

Disorders)

Dated: September 4, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–23896 Filed 9–9–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Natiional Institutes of Health

National Institute on Alcohol Abuse

and Alcoholism; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Purpose/Agenda: To review and evaluate

grant applications.

Name of Committee: National Institute on

Alcohol Abuse and Alcoholism Special

Emphasis Panel.

Date of Meeting: September 12, 1997.

Time: 8:30 a.m. to adjournment.

Place of Meeting: Holiday Inn, 5520

Wisconsin Avenue, Bethesda, MD 20815.

Contact Person: Elsie Taylor, 6000

Executive Boulevard, Suite 409, Rockville,

MD 20892–7003, 301–443–9787.

The meeting will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The

proposal and discussions could reveal

confidential trade secrets or commercial

property such as patentable material, and

personal information concerning individuals

associated with the proposal, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

(Catalog of Federal Domestic Assistance,

Program Nos. 93.271, Alcohol Research

Career Development Awards for Scientists

and Clinicians; 93.272, Alcohol National

Research Service Awards for Research

Training; 93.273, Alcohol Research Programs;

93.891, Alcohol Research Center Grants;

National Institutes of Health)

Dated: September 4, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–23898 Filed 9–9–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: For Nucleic Acid-Based

Vaccines and Therapeutics

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is a notice in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of a limited field of use

exclusive license in the United States to

practice the invention embodied in U.S.

Patent Application Number 08/286,730

entitled, ‘‘Liposomal Delivery System

for Nucleic Acids,’’ and its

Continuation-In-Part U.S. Patent

Application Serial Number 08/522,246,

and all related foreign filings (PCT/

US95/09867), invented by Alain Thierry

formerly of the National Cancer

Institute, to Biovector Therapeutics, S.A

of Labage, France. The patent rights in

these inventions have been assigned to

the United States of America.

DATES: Only written comments and/or

applications for a license which are

received by NIH on or before December

9, 1997 will be considered.

ADDRESSES: Requests for copies of the

subject issued patent and pending

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Mr. Larry M. Tiffany, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD

20852; Telephone: (301) 496–7056, ext.

206; Facsimile: (301) 402–0220. A

signed Confidentiality Agreement will

be required to receive copies of the

pending patent applications.

SUPPLEMENTARY INFORMATION: The

present invention relates to a liposome

composition comprising a bi- or multilayered membrane surrounding an

internal aqueous liposome comprising

at least one cationic lipopolyamine and

at least one neutral lipid provided in a

molar ratio range, said ratio from about

.02:1 to 2:1. In addition to the pending

composition claims there are also

pending rights to methods of preparing

the liposome composition,

pharmaceutical compositions including

the liposome and methods of

introducing nucleic acids into cells

using the liposome. This invention is

advantageous over alternative lipid

preparations due to its ability to more